Company Overview
Pulmonx Corporation operates as a commercial-stage medical technology company dedicated to providing minimally invasive treatment solutions for patients suffering from severe emphysema, a specific and serious form of chronic obstructive pulmonary disease. The company functions within the broader Healthcare sector, specifically targeting the Medical Devices industry, where it develops specialized hardware to address respiratory conditions. Currently, the organization employs a workforce of 296 individuals and holds a market capitalization of $49.42M while reporting total annual revenue of $90.50M. These financial figures indicate that Pulmonx is a mid-cap entity with a revenue base that is substantial relative to its market valuation, suggesting a company that has generated significant top-line activity but is currently trading at a valuation significantly below its reported revenue multiple.
Financial Health
The company reported revenue of $90.50M over the trailing twelve months, yet this top-line activity masks a significant operational challenge, as the net income for the same period was -$54,003,000 and EBITDA stood at -$52,609,000. The substantial gap between the positive revenue of $90.50M and the large negative net income reveals a cost structure where expenses, including the costs of goods sold and operating expenditures, heavily outweigh the gross revenue generated. Furthermore, the free cash flow is reported at -$12,531,250, which indicates that the company is burning cash on an annualized basis rather than generating liquidity from its operations. On the margins side, the gross margin is 74.2%, suggesting that the cost of producing or sourcing the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System is relatively low compared to the sales price. However, the operating margin of -43.8% and the profit margin of -59.7% demonstrate that high operating expenses, likely related to research, development, and general administration, are eroding profitability significantly. Regarding liquidity and leverage, the company holds $69.75M in cash against $56.36M in debt, resulting in a debt-to-equity ratio of 104.15 which suggests a leveraged balance sheet where liabilities exceed equity. Despite the leverage, the current ratio of 5.07 indicates a very strong short-term liquidity position, as current assets are more than five times the value of current liabilities. Finally, the return on equity is -77.2% and the return on assets is -23.0%, metrics that reveal that management effectiveness in generating returns on the capital invested has been negative due to the ongoing losses.
Valuation Assessment
The valuation metrics for Pulmonx show a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed at -1.16, implying that future earnings expectations are currently modeled as negative or not yet profitable. The price-to-book ratio is 0.90, which indicates that the market values the company at roughly 90% of its net asset value, suggesting no market premium over book value and potentially a discount for the negative earnings profile. Additionally, the price-to-sales ratio is 0.55 and the EV/EBITDA is -0.69, metrics that suggest the market is pricing the stock based on revenue multiples rather than earnings power, typical for a pre-profitability medical device company. The stock has a 52-week high of $7.96 and a 52-week low of $1.14, meaning the current trading price sits within a range that reflects high volatility but is currently below the yearly peak. The beta value is 0.12, which indicates that the stock's price volatility is significantly lower than the broader market, moving less than one-seventh as much as the S&P 500 in response to general market movements.
Growth & Income
Revenue growth year-over-year is -4.9%, and earnings growth is listed as N/A because the company has not recorded positive earnings to calculate a growth rate. Since earnings are not growing while revenue is contracting slightly, the company is currently in a phase of contraction rather than expansion, which implies that the business model is not yet self-sustaining in terms of profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flow is reinvested into the business or used to cover operational deficits rather than distributed to shareholders. Consequently, the overall growth and income profile for Pulmonx is characterized by negative revenue momentum and a complete absence of income generation for shareholders, reflecting the high-risk nature of a medical device company that has not yet achieved commercial profitability.